{"entity":{"id":"funda-meric-bernstam","kind":"person","name":"Funda Meric-Bernstam","aka":[],"tldr":"Funda Meric-Bernstam runs the world's largest phase 1 programme and led the tumour-agnostic HER2 ADC study.","summary":"Funda Meric-Bernstam is Chair of Investigational Cancer Therapeutics at MD Anderson Cancer Center, where she runs the world's largest phase 1 programme. A surgical oncologist turned early-drug-development leader, she directs MD Anderson's Institute for Personalized Cancer Therapy and chaired DESTINY-PanTumor02, the trial that led to the tumour-agnostic approval of trastuzumab deruxtecan for HER2 IHC 3+ solid tumours. Her papers report the primary results of the DESTINY-PanTumor02 phase II trial of trastuzumab deruxtecan in HER2-expressing solid tumours and the feasibility of large-scale genomic testing to enrol patients onto genomically matched trials. Her work spans precision oncology, comprehensive genomic profiling and companion diagnostics.","asOf":"2026-09-08","links":[{"label":"MD Anderson faculty","url":"https://faculty.mdanderson.org/search?q=Funda%20Meric-Bernstam"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Meric-Bernstam%20F%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Funda%20Meric-Bernstam"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["cgp","companion-diagnostic"],"targets":["her2"],"drugs":["trastuzumab-deruxtecan"],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":["destiny-pantumor02"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chair, Investigational Cancer Therapeutics, MD Anderson","institutionId":"md-anderson","specialisms":["Phase 1 trials","Precision oncology","HER2"],"profiles":[{"label":"MD Anderson faculty","url":"https://faculty.mdanderson.org/search?q=Funda%20Meric-Bernstam"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Meric-Bernstam%20F%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Funda%20Meric-Bernstam"}],"papers":[{"title":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial","journal":"Journal of Clinical Oncology","year":2024,"url":"https://doi.org/10.1200/JCO.23.02005","doi":"10.1200/JCO.23.02005"},{"title":"Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials","journal":"Journal of Clinical Oncology","year":2015,"url":"https://doi.org/10.1200/JCO.2014.60.4165","doi":"10.1200/JCO.2014.60.4165"}]},"route":"/people/funda-meric-bernstam/","neighbours":{"technology":[{"id":"companion-diagnostic","kind":"technology","name":"Companion diagnostics","route":"/technologies/companion-diagnostic/"},{"id":"cgp","kind":"technology","name":"Comprehensive genomic profiling","route":"/technologies/cgp/"}],"target":[{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"}],"drug":[{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/"}],"institution":[{"id":"md-anderson","kind":"institution","name":"MD Anderson Cancer Center","route":"/institutions/md-anderson/"}],"trial":[{"id":"destiny-pantumor02","kind":"trial","name":"DESTINY-PanTumor02","route":"/trials/destiny-pantumor02/"},{"id":"mypathway","kind":"trial","name":"MyPathway","route":"/trials/mypathway/"}]}}